Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rebecca Moroose

Medical Oncology Orlando, FL Medical Doctor

NPI 1972503159 CMS profile 362319

22 W Underwood St, Orlando, FL 32806

Open in the dashboard

General payments

$542,660

588 records reported · program years 2019–2025

Research payments

$12,757

Paid to them · 6 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$414,180 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Rebecca Moroose of Orlando, FL is reported in the CMS Open Payments database as having received $542,660 across 588 general payments and $12,757 in research payments paid to them. Separately, studies naming them as principal investigator received $414,180 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 Research $1,773 2
2024 Research $3,048 1
2023 General $1,620 3
2023 Research $4,116 1
2022 General $157,740 136
2021 General $126,523 106
2021 Research $3,820 2
2020 General $112,144 149
2019 General $144,633 194

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rebecca Moroose
  • Medical Oncology median
  • Middle half of Medical Oncology
  • National median

In program year 2025, general payments to Rebecca Moroose were reported at $0. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.

Show as a table
Year Rebecca Moroose Medical Oncology median Middle half National median
2019 $144,633 $968 $140–$6,658 $163
2020 $112,144 $747 $102–$5,891 $114
2021 $126,523 $430 $50–$4,098 $132
2022 $157,740 $812 $127–$4,907 $149
2023 $1,620 $957 $144–$5,248 $160
2024 $0 $1,042 $149–$5,650 $164
2025 $0 $1,128 $147–$5,675 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $331,351 413 payments
  2. Gilead Sciences, Inc. $103,640 70 payments
  3. Seattle Genetics, Inc. $49,931 48 payments
  4. Pfizer Inc. $25,764 29 payments
  5. Immunomedics, Inc. $13,772 9 payments
  6. Genentech USA, Inc. $11,086 10 payments
  7. Novartis Pharmaceuticals Corporation $2,965 2 payments
  8. Ethicon Inc. $1,628 3 payments
  9. Eli Lilly Export S.A. Puerto Rico Branch $1,400 1 payment
  10. E.R. Squibb & Sons, L.L.C. $990 1 payment
  11. Other $134 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $438,890 167 payments
  2. Travel and Lodging $66,840 245 payments
  3. Consulting Fee $29,633 13 payments
  4. Food and Beverage $7,224 160 payments
  5. Education $73 3 payments
Products named General payments · program years 2019–2025
  1. VERZENIO $288,581 251 payments
  2. Trodelvy Onc $103,628 69 payments
  3. TUKYSA $41,937 39 payments
  4. TALZENNA $21,266 21 payments
  5. TRODELVY Oncology $13,772 9 payments
  6. Kadcyla $11,086 10 payments
  7. IBRANCE $4,614 9 payments
  8. PIQRAY $2,965 2 payments
  9. STRATAFIX $1,628 3 payments
  10. VICRYL $1,515 2 payments
  11. Other $4,037 6 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $8,937 4 payments
  2. Pfizer Inc. $3,820 2 payments

Records

594 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Medical Oncology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record